Search results
Author(s):
Harriette Van Spall
,
Stephen Nicholls
Added:
6 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in…
View more
Obesity in Focus
Author(s):
Chim C Lang
,
Bianca Rocca
,
Samira Bell
Added:
8 months ago
Video
Author(s):
Harriette Van Spall
,
Roland RJ van Kimmenade
Added:
1 year ago
ACC 25 - FRESH-UP shows liberal fluid intake did not result in a significant difference in health status compared to fluid restriction of 1500ml per day, but did result in a lower perceived thirst distress.Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Roland Van Kimmenade (Radboud University Medical Center, Nijmegen, NL) to discuss the findings from the multi-center,…
View more
Author(s):
Nicolas Girerd
Added:
2 years ago
HFA 2024 — Investigator, Prof Nicolas Girerd (University Hospital of Nancy, FR) joins us to discuss the findings from the TELESAT study (NCT06312501).This multicenter observational longitudinal cohort study investigated whether a Remote Patient Monitoring (RPM) program (Satelia®Cardio, Satelia) is able to prevent cardiac decompensation by detecting weak signals of decompensation early in patients…
View more
Author(s):
James Udelson
Added:
1 year ago
THT Conference 2025 - Positive safety and efficacy outcomes were found of the Reprieve decongestion management system (DMS; Reprieve Cardiovascular, Inc) for the treatment of acute decompensated heart failure (ADHF). Urinary sodium excretion was seen to be significantly higher in the Reprieve DMS arm than in the control arm, and there were fewer UTI infections in ADHF patients receiving the…
View more
Author(s):
Lars H Lund
Added:
2 weeks ago
HFA Congress 2026 — Dr Lars Lund (Karolinska Institute and Karolinska University Hospital, Stockholm, SE) joins us to discuss findings from GOAL-HF1, a randomised, double-blind, placebo-controlled phase 1b/2a trial evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF).This first-in-patient study assessed the safety, tolerability and exploratory efficacy of AC01 — a…
View more
Author(s):
Diana Hui Ping Foo
Added:
1 year ago
ESC HF 25 - Findings from Heart2Miss suggest a hub-and-spoke model for early heart failure detection can detect patients with pre-HF and HF who were previously undiagnosed, can reduce tertiary center overload and improve novice performance.Dr Diana Foo (Sarawak General Hospital, Kuching, MY) discusses the findings from the Heart2Miss study, investigating a decentralised, community-based, rapid,…
View more
Author(s):
Ankeet Bhatt
Added:
1 year ago
ESC HF 25 - Secondary analysis of the FINEARTS-HF study shows finerenone treatment favourably influenced the risk of early heart failure readmission.Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, San Francisco, US) discusses findings from the prespecified secondary analysis of the FINEARTS-HF trial (NCT04435626; Bayer). The placebo-controlled primary analysis investigated the…
View more
Author(s):
Stefan Stork
Added:
1 year ago
ESC HF 25 - A secondary analysis of TIM-HF2 showed that patients residing farther from their cardiologist benefited further from remote patient management (RPM).Prof Stefan Störk (University Hospital Wuerzburg, DE) discusses the findings from a pre-specified, secondary analysis of TIM-HF2, investigating the impact of rurality and travel distance on the effectiveness of RPM in patients…
View more
Author(s):
Nicolas Girerd
Added:
1 year ago
ESC HF 25 - Real-world findings suggest kidney function decline could precede heart failure events by up to a year.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses real-world findings from pooled trials EPHESUS, EMPHASIS-HF and BARCELONA. The study investigated if longitudinal changes in kidney function could help identify patients with HFrEF at a higher risk of…
View more